Early data suggests three doses of Pfizer and BioNTech's COVID-19 vaccine provides protection against the new Omicron variant, the companies say.
Pfizer and BioNTech announced Wednesday that a third dose of its COVID-19 vaccine offers a similar amount of protection against the new Omicron variant as two doses of the vaccine does against the original strain of the coronavirus, NBC News reports. The companies also said, however, that preliminary studies indicate two doses "may not be sufficient to protect against infection with the Omicron variant," and a third dose provides "more robust" protection.
"Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it's clear from these preliminary data that protection is improved with a third dose of our vaccine," Pfizer CEO Albert Bourla said. "Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
BioNTech CEO Ugur Sahin added that "our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant."
The news comes less than two weeks after the World Health Organization designated the new Omicron variant a variant of concern. Asked on the Today show whether this new data suggests a two-shot Pfizer regime is "effectively useless" against Omicron, Bourla stressed that there still is "tremendous value" in receiving two doses "compared to if you only have one or if you don't have any."
Bourla added, "It might not be enough on itself, but we are waiting to see. So you may need to go to get the third booster faster, and that's something that the health authorities should consider very carefully and make their recommendations."
-
Five takeaways from Plaid Cymru’s historic Caerphilly by-election winThe Explainer The ‘big beasts’ were ‘humbled’ but there was disappointment for second-placed Reform too
-
A journey through Trinidad’s wild heartThe Week Recommends Experience the island’s natural wonders, from watching baby turtles hatch to visiting an ancient bat cave
-
Will latest Russian sanctions finally break Putin’s resolve?Today's Big Question New restrictions have been described as a ‘punch to the gut of Moscow’s war economy’
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
